Skip to main content
. 2015 Jun 1;145(4):583–596. doi: 10.1111/imm.12476

Figure 6.

Figure 6

Treatment with CC-chemokine receptor 5 (CCR5) antagonists before but not after infection resembles the phenotype of CCR5-deficient mice. Wild-type (WT) mice were treated daily with 10 μg of Met-RANTES 1 day before infection until day 6 p.i. (Pre-Treatment) or on day 3 until day 6 p.i. (Post-Treatment). Mice were inoculated with 200 plaque-forming units (PFU) of DENV-2 P23085 and killed at day 7 p.i. for sample collection. (a) Viral loads in spleen, liver and blood were measured by plaque assays. (b) Haematocrit and platelet count, as indicators of haematological alteration. (c) Interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) levels in spleen homogenates and (d) neutrophil accumulation in the spleen (left) and liver (right) as indicated by myeloperoxidase (MPO) activity. (e) DENV-2 induction of CCR5 ligands CCL3, CCL4 and CCL5 in the spleen as evaluated by ELISA. (f) Survival rates of DENV-2 P23085-infected WT mice treated with the CCR5 antagonist UK-484900 before (Pre-Treatment) and after (Post-Treatment) infection. Data are representative of two independent experiments. *P < 0·05, ***P < 0·001 when compared to positive controls.